In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Commentary|Videos|May 22, 2026
Advances in Molecular Profiling and GLP-1 Therapy Offer Hope in Endometrial Cancer
Fact checked by: Kirsty Mackay
GLP-1 receptor agonists, molecular profiling, and biomarker-driven treatment strategies may help improve outcomes and personalize care for patients at risk for or diagnosed with endometrial cancer.
Advertisement
In this interview with Pharmacy Times, Jennifer MacDonald, PharmD, BCOP, director of the Medical University of South Carolina Oncology PGY2 Residency Program and clinical oncology pharmacy specialist at Hollings Cancer Center, discusses the evolving role of molecular profiling and glucagon-like peptide-1 (GLP-1) receptor agonists in the management of endometrial cancer. MacDonald explains how biomarker-driven treatment selection is reshaping uterine cancer care, particularly as clinicians move beyond traditional staging to incorporate molecular classifications such as POLE mutations, mismatch repair status, p53 alterations, and HER2 expression into therapeutic decision-making. She highlights the growing role that pharmacists play in interpreting complex molecular assay results and guiding personalized treatment strategies.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
The Value of Self-Monitoring Blood Glucose Tools in Preventing and Reducing Prediabetes and Diabetes-Related Complications
3
Using CKDintercept to Build Interdisciplinary Kidney Care
4
2026 AHA Endocarditis Guidelines Expand Outpatient Antibiotic Options
5